Monkeypox Concept(BK4583),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4583 Monkeypox Concept

Market Closed 12-12 16:00:00 EST

1,657.44

-30.02

-1.78%

High1,693.54	Low1,646.60	Vol16.39M
Open1,687.43	D1 Closing1,687.46	Amplitude2.78%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O1.12B	T/O Rate--	Tradable Shares0.00
P/B4.1715	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1657.4404,"timestamp":1765573199999,"preClose":1687.4576,"halted":0,"volume":16393209,"delay":0,"changeRate":-0.017788,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-30.017212,"latestTime":"12-12 16:00:00 EST","open":1687.4282,"high":1693.5409,"low":1646.6013,"amount":1118478569.143483,"amplitude":0.027817,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.1715,"peRate":35.527409,"turnoverRate":0.006067,"increases":3,"decrements":6,"flats":1,"marketCap":184551499842.25,"floatMarketCap":184019102575.5},"requestUrl":"/m/hq/s/BK4583/tweets","defaultTab":"tweets","newsList":[{"id":"2591168406","title":"GeoVax Labs: Files for Prospectus Relates to Public Offering of 18.3 Mln Units - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2591168406","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591168406?lang=en_us&edition=fundamental","pubTime":"2025-12-13 06:32","pubTimestamp":1765578735,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XI1CQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GOVX","BK4139","BK4583"],"gpt_icon":0},{"id":"2591685761","title":"Arcus Revamps Cancer Pipeline Following Trial Miss, Prioritizes Kidney Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2591685761","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591685761?lang=en_us&edition=fundamental","pubTime":"2025-12-13 02:35","pubTimestamp":1765564500,"startTime":"0","endTime":"0","summary":"Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC data and key 2026 milestones.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/12/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/12/Medical-Development-Laboratory-Caucasian.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49370717/arcus-revamps-cancer-pipeline-following-trial-miss-prioritizes-kidney-drug","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/25/12/49370717/arcus-revamps-cancer-pipeline-following-trial-miss-prioritizes-kidney-drug","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4566","LU0289739699.SGD","LU2089984988.USD","BK4585","LU1674673691.USD","LU2468319806.SGD","RCUS","BK4097","LU0058720904.USD","LU1778281490.HKD","LU2087621335.USD","IE00B19Z3B42.SGD","BK4583","BK4578","LU1674673428.USD","LU0882574055.USD","LU0109394709.USD","LU0234570918.USD","IE00B19Z3581.USD","LU1585245621.USD","LU1066051498.USD","BK4532","LU0889565916.HKD","OS","SG9999015945.SGD","SG9999015986.USD","IE0002270589.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4139","SG9999015978.USD","IE00B7SZLL34.SGD","SG9999015952.SGD","LU2324357040.USD","BK4568","IE00B3T34201.USD","GILD","LU1571399168.USD","LU0114720955.EUR","LU1430594728.SGD","LU1066053197.SGD","BK4588","BK4550","IE00BSNM7G36.USD","LU0320765992.SGD","LU1839511570.USD","LU0823416689.USD"],"gpt_icon":0},{"id":"2590796501","title":"Arcus Biosciences to Discontinue Phase 3 Trial of Potential Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2590796501","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590796501?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:46","pubTimestamp":1765547160,"startTime":"0","endTime":"0","summary":"Arcus Biosciences said it will discontinue a late-stage trial for its potential cancer treatment due to futility.The study, which was being conducted in partnership with Gilead Sciences, aimed to evaluate STAR-221 as a first-line treatment for advanced gastric and esophageal cancers.The biopharmaceutical company said Friday that an interim analysis of results showed that STAR-221 didn't improve overall survival relative to existing treatment options. The safety profile for the treatment was similar to that of existing options, and no new safety findings were identified, it added.The decision to end the trial was based on the recommendation of an independent data monitoring committee. Arcus and Gilead said they are communicating with investigators to determine appropriate next steps for patients in the study, in addition to conducting a detailed analysis to better understand the results.\"We are disappointed with this outcome and sincerely thank all those who participated in the study an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD","BK4566","BK4139","IE00BZ1G4Q59.USD","LU0058720904.USD","LU1571399168.USD","LU0889565916.HKD","LU1839511570.USD","LU1066053197.SGD","SG9999015986.USD","IE00BKVL7J92.USD","SG9999015978.USD","LU0882574055.USD","LU1585245621.USD","LU0234570918.USD","SG9999015952.SGD","BK4568","IE0002270589.USD","LU1430594728.SGD","IE00B19Z3B42.SGD","LU2089984988.USD","LU0823416689.USD","LU2087621335.USD","LU1778281490.HKD","LU0289739699.SGD","LU0114720955.EUR","BK4550","IE00B19Z3581.USD","BK4578","RCUS","IE00B7SZLL34.SGD","SG9999015945.SGD","LU1674673691.USD","IE00BSNM7G36.USD","BK4585","LU2468319806.SGD","BK4532","LU0320765992.SGD","LU1066051498.USD","LU1674673428.USD","BK4583","BK4588","LU0109394709.USD","IE00B3T34201.USD","LU2324357040.USD"],"gpt_icon":0},{"id":"2590501926","title":"BRIEF-Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501926","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501926?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:39","pubTimestamp":1765546793,"startTime":"0","endTime":"0","summary":"BRIEF-Arcus Provides Update On Phase 3 STAR-221 Study And Concentrates Its Research And Development Investment On Casdatifan And Emerging Inflammation And Immunology PortfolioDec 12 (Reuters) - Arcus ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUAGYNPZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","IE00B3T34201.USD","LU1066053197.SGD","LU2087621335.USD","LU0889565916.HKD","BK4139","BK4532","LU1066051498.USD","LU1839511570.USD","LU2468319806.SGD","BK4588","SG9999015945.SGD","LU0234570918.USD","LU1430594728.SGD","RCUS","LU1585245621.USD","IE00B19Z3B42.SGD","SG9999015986.USD","BK4550","BK4568","LU0289739699.SGD","IE0002270589.USD","LU2089984988.USD","LU1674673691.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU1778281490.HKD","LU0114720955.EUR","SG9999015952.SGD","BK4578","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4566","GILD","LU1571399168.USD","LU0823416689.USD","LU0882574055.USD","SG9999015978.USD","LU2324357040.USD","BK4585","IE00BSNM7G36.USD","BK4583","LU0320765992.SGD","LU1674673428.USD","LU0109394709.USD"],"gpt_icon":0},{"id":"2590350164","title":"BRIEF-Gilead: Discontinuation Of Phase 3 STAR-221 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2590350164","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590350164?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:30","pubTimestamp":1765546246,"startTime":"0","endTime":"0","summary":"BRIEF-Gilead: Discontinuation Of Phase 3 STAR-221 StudyDec 12 (Reuters) - Gilead Sciences Inc GILD.O:GILEAD: DISCONTINUATION OF PHASE 3 STAR-221 STUDYGILEAD: DISCONTINUATION DECISION BASED ON RECOMMEN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XH1JB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3T34201.USD","LU1430594728.SGD","LU1066051498.USD","LU0320765992.SGD","LU1839511570.USD","IE00BZ1G4Q59.USD","GILD","IE00B19Z3B42.SGD","SG9999015945.SGD","IE00BSNM7G36.USD","LU0823416689.USD","SG9999015978.USD","BK4532","LU0234570918.USD","SG9999015986.USD","LU0109394709.USD","LU2089984988.USD","LU2468319806.SGD","LU0058720904.USD","LU1571399168.USD","IE00B19Z3581.USD","BK4583","LU1585245621.USD","BK4585","LU0889565916.HKD","BK4568","IE00BKVL7J92.USD","LU1674673691.USD","LU2087621335.USD","IE0002270589.USD","LU0289739699.SGD","IE00B7SZLL34.SGD","BK4139","BK4578","LU1778281490.HKD","BK4566","LU2324357040.USD","LU0114720955.EUR","SG9999015952.SGD","BK4588","LU1674673428.USD","LU0882574055.USD","BK4550","LU1066053197.SGD"],"gpt_icon":0},{"id":"2590501641","title":"FDA Approves Emergent BioSolutions Winnipeg Facility for Raxibacumab Manufacturing","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501641","media":"Reuters","labels":["productRelease","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501641?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:30","pubTimestamp":1765546223,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions Inc. has received approval from the U.S. Food and Drug Administration  for its supplemental Biologics License Application , allowing its Winnipeg, Canada facility to serve as the drug product manufacturing and testing site for raxibacumab, a monoclonal antibody used for the treatment and prevention of inhalational anthrax. This regulatory approval supports Emergent's ongoing transformation strategy by strengthening its manufacturing network and consolidating operations in Winnipeg, Canada and Lansing, Michigan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via GlobeNewswire  on December 12, 2025, and is solely responsible f","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDLbJPqmJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","LU0314104364.USD","SG9999014021.USD","BK4583","EBS","NDAQ","IE00BGHQF748.EUR","SG9999014039.USD","SG9999014005.SGD","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4139","IE00BKPKM429.USD","LU2095319765.USD","BK4588","SG9999014013.SGD","LU2210150020.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2590688501","title":"Arcus Biosciences Inc: Star-221 and Phase 2 Edge-Gastric Studies Will Be Discontinued","url":"https://stock-news.laohu8.com/highlight/detail?id=2590688501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590688501?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:30","pubTimestamp":1765546201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUAGYNPZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1571399168.USD","LU0889565916.HKD","LU1778281490.HKD","BK4585","LU2087621335.USD","LU0114720955.EUR","LU0109394709.USD","GILD","IE00B19Z3B42.SGD","LU2324357040.USD","LU2089984988.USD","LU0882574055.USD","IE0002270589.USD","LU2468319806.SGD","IE00B19Z3581.USD","IE00B3T34201.USD","BK4139","LU0058720904.USD","LU1430594728.SGD","IE00BSNM7G36.USD","LU0823416689.USD","BK4532","IE00B7SZLL34.SGD","LU1585245621.USD","LU0289739699.SGD","SG9999015945.SGD","IE00BZ1G4Q59.USD","LU0234570918.USD","LU1066051498.USD","BK4583","LU1674673691.USD","BK4578","RCUS","LU1839511570.USD","LU1674673428.USD","BK4566","BK4550","IE00BKVL7J92.USD","BK4568","SG9999015986.USD","BK4588","SG9999015978.USD","LU0320765992.SGD","LU1066053197.SGD","SG9999015952.SGD"],"gpt_icon":0},{"id":"2590501302","title":"Emergent BioSolutions Receives U.S. FDA Approval for Drug Product Manufacturing of Raxibacumab at Its Winnipeg, Canada Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501302?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:30","pubTimestamp":1765546200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nTUA65MSSZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EBS","BK4139","BK4583"],"gpt_icon":0},{"id":"2590850136","title":"Gilead: Discontinuation Decision Based on Recommendation From Independent Data Monitoring Committee","url":"https://stock-news.laohu8.com/highlight/detail?id=2590850136","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590850136?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:27","pubTimestamp":1765546034,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XH1JB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0058720904.USD","BK4583","IE00BZ1G4Q59.USD","LU1674673428.USD","SG9999015945.SGD","IE00BKVL7J92.USD","BK4585","LU0823416689.USD","IE00B7SZLL34.SGD","IE0002270589.USD","BK4578","BK4568","LU0109394709.USD","IE00B3T34201.USD","BK4532","LU0114720955.EUR","LU0234570918.USD","LU0882574055.USD","LU1066051498.USD","LU1571399168.USD","BK4588","SG9999015978.USD","LU1839511570.USD","LU1585245621.USD","LU1430594728.SGD","SG9999015952.SGD","GILD","LU2468319806.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU2324357040.USD","LU0320765992.SGD","BK4139","LU1066053197.SGD","LU1674673691.USD","BK4550","SG9999015986.USD","IE00BSNM7G36.USD","LU0289739699.SGD","LU1778281490.HKD","LU0889565916.HKD","BK4566","LU2087621335.USD","LU2089984988.USD"],"gpt_icon":0},{"id":"2590501394","title":"Gilead: No Changes to Other Ongoing Domvanalimab Studies Beyond Upper Gastrointestinal Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501394","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501394?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:27","pubTimestamp":1765546034,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XH1JB:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4532","LU1839511570.USD","LU0823416689.USD","SG9999015986.USD","LU1066051498.USD","LU1778281490.HKD","BK4585","LU2468319806.SGD","SG9999015952.SGD","SG9999015978.USD","GILD","IE00B19Z3B42.SGD","BK4568","BK4583","IE0002270589.USD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4139","LU0114720955.EUR","LU1571399168.USD","LU1066053197.SGD","LU0289739699.SGD","LU0889565916.HKD","LU1430594728.SGD","LU2089984988.USD","IE00B3T34201.USD","IE00BSNM7G36.USD","BK4588","LU0058720904.USD","LU2324357040.USD","LU0320765992.SGD","BK4578","IE00B19Z3581.USD","SG9999015945.SGD","LU1585245621.USD","LU1674673428.USD","LU2087621335.USD","IE00B7SZLL34.SGD","LU1674673691.USD","LU0882574055.USD","LU0234570918.USD","LU0109394709.USD","BK4566","BK4550"],"gpt_icon":0},{"id":"2590399501","title":"Gilead -  in Interim Analysis, Combination of Domvanalimab Plus Zimberelimab & Chemotherapy Did Not Improve Os Relative to Nivolumab Plus Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2590399501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590399501?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:27","pubTimestamp":1765546034,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XH1JB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1571399168.USD","SG9999015952.SGD","IE00BZ1G4Q59.USD","LU0234570918.USD","GILD","LU1674673691.USD","LU0114720955.EUR","BK4583","SG9999015978.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","LU0882574055.USD","IE0002270589.USD","LU1674673428.USD","LU1066053197.SGD","LU1585245621.USD","LU2089984988.USD","SG9999015945.SGD","BK4568","LU1066051498.USD","BK4588","LU2087621335.USD","LU1778281490.HKD","LU0320765992.SGD","IE00BKVL7J92.USD","LU0289739699.SGD","BK4585","IE00B3T34201.USD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","BK4139","BK4550","LU0109394709.USD","LU1839511570.USD","SG9999015986.USD","IE00B19Z3581.USD","LU1430594728.SGD","BK4566","LU0823416689.USD","BK4578","BK4532","LU0058720904.USD","LU2324357040.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2590358501","title":"Gilead: Discontinuation of Phase 3 Star-221 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2590358501","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590358501?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:27","pubTimestamp":1765546034,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XH1JB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1430594728.SGD","BK4583","LU0109394709.USD","LU0823416689.USD","GILD","LU2324357040.USD","LU1066053197.SGD","LU1674673428.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","BK4566","SG9999015978.USD","BK4139","IE00B7SZLL34.SGD","BK4568","LU0114720955.EUR","LU1839511570.USD","IE00BSNM7G36.USD","LU1571399168.USD","LU2087621335.USD","IE00B3T34201.USD","LU1778281490.HKD","BK4532","BK4550","LU2089984988.USD","IE00BZ1G4Q59.USD","LU2468319806.SGD","LU0320765992.SGD","LU0882574055.USD","IE00BKVL7J92.USD","SG9999015945.SGD","SG9999015986.USD","SG9999015952.SGD","IE0002270589.USD","LU1066051498.USD","LU0234570918.USD","BK4588","LU1674673691.USD","LU1585245621.USD","LU0058720904.USD","BK4585","BK4578","IE00B19Z3581.USD","LU0289739699.SGD"],"gpt_icon":0},{"id":"2590150139","title":"Gilead - No New Safety Findings for Combination of Domvanalimab Plus Zimberelimab","url":"https://stock-news.laohu8.com/highlight/detail?id=2590150139","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590150139?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:27","pubTimestamp":1765546034,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nFWN3XH1JB:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0320765992.SGD","IE00BKVL7J92.USD","LU1674673428.USD","SG9999015978.USD","BK4583","BK4566","LU1066053197.SGD","SG9999015952.SGD","GILD","BK4532","LU2087621335.USD","LU1778281490.HKD","LU0114720955.EUR","LU0234570918.USD","BK4585","BK4578","LU1585245621.USD","LU1674673691.USD","BK4139","LU2089984988.USD","BK4550","IE00B19Z3581.USD","LU1571399168.USD","LU1839511570.USD","LU0823416689.USD","IE00BZ1G4Q59.USD","LU1430594728.SGD","LU0289739699.SGD","LU0058720904.USD","IE0002270589.USD","BK4568","LU2324357040.USD","SG9999015945.SGD","IE00BSNM7G36.USD","SG9999015986.USD","LU0889565916.HKD","LU1066051498.USD","IE00B7SZLL34.SGD","IE00B3T34201.USD","LU0109394709.USD","IE00B19Z3B42.SGD","LU0882574055.USD","BK4588","LU2468319806.SGD"],"gpt_icon":0},{"id":"2590501844","title":"Gilead Halts Phase 3 STAR-221 Trial After Domvanalimab Combo Fails to Improve Survival in Gastric Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590501844","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590501844?lang=en_us&edition=fundamental","pubTime":"2025-12-12 21:23","pubTimestamp":1765545790,"startTime":"0","endTime":"0","summary":"Gilead Sciences Inc. and Arcus Biosciences announced the discontinuation of the Phase 3 STAR-221 study, which evaluated the anti-TIGIT antibody domvanalimab in combination with the anti-PD-1 antibody zimberelimab and chemotherapy versus nivolumab plus chemotherapy as first-line treatment for HER2-negative advanced gastric and esophageal cancers. The decision follows a recommendation from the Independent Data Monitoring Committee after a pre-specified interim analysis indicated that the domvanalimab combination did not improve overall survival compared to the current standard of care. The safety profile was consistent between both treatment arms, with no new safety findings. Results from a detailed analysis of the study will be published in the future. Domvanalimab and zimberelimab are investigational and have not received regulatory approval for any use.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provid","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251212:nNDL13nhcz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","LU0889565916.HKD","LU2468319806.SGD","LU1778281490.HKD","RCUS","GILD","BK4139","LU0320765992.SGD","LU1585245621.USD","BK4585","LU0234570918.USD","BK4532","LU0109394709.USD","IE00B3T34201.USD","LU1571399168.USD","LU1839511570.USD","LU2087621335.USD","IE00B19Z3581.USD","BK4588","LU1430594728.SGD","LU1674673428.USD","BK4550","SG9999015978.USD","LU0823416689.USD","BK4566","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4578","LU0114720955.EUR","LU2089984988.USD","IE0002270589.USD","IE00BSNM7G36.USD","SG9999015986.USD","BK4583","LU2324357040.USD","LU1066051498.USD","SG9999015945.SGD","LU1066053197.SGD","LU0882574055.USD","LU1674673691.USD","SG9999015952.SGD","LU0289739699.SGD","BK4568"],"gpt_icon":0},{"id":"2590440005","title":"Inovio Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2590440005","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590440005?lang=en_us&edition=fundamental","pubTime":"2025-12-12 06:26","pubTimestamp":1765491960,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Inovio Pharmaceuticals Inc.  slipped 1.84% to $2.13 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average  rising 1.34% to 48,704.01 and the NASDAQ Composite Index  falling 0.25% to 23,593.86.This was the stock's second consecutive day of losses.Inovio Pharmaceuticals Inc. closed 47.79% short of its 52-week high of $4.08, which the company reached on December 12th.The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson  rose 1.68% to $210.01, Statera Biopharma Inc.  remained unchanged, and Pfizer Inc.  rose 0.08% to $25.80.Trading volume  remained 275,281 below its 50-day average volume of 1.2 M.Data source: Dow Jones Market Data, FactSet. Data compiled December 11, 2025.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is publis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0795875086.SGD","LU1929549753.HKD","IE00B42XCP33.USD","BK4599","LU1066053197.SGD","IE00B2B36J28.USD","LU1196500208.SGD","IE00BSNM7G36.USD","LU0321505439.SGD","LU0432979614.USD","LU0882574055.USD","IE00B3T34201.USD","BK4585","LU2471134879.HKD","IE00BKVL7J92.USD","IE00BFTCPJ56.SGD","IE00BZ1G4Q59.USD","SG9999002232.USD","IE0002141913.USD","IE0009355771.USD","LU0795875169.SGD","BK4007","LU2471134952.CNY","IE00BVYPNV92.GBP","LU1883839398.USD","LU1267930813.SGD","SG9999013999.USD","SG9999002224.SGD","LU2592432038.USD","IE00BLSP4239.USD","LU1032466523.USD","LU1032955483.USD","LU2112291526.USD","BK4581","LU1244550577.SGD","LU2129689605.HKD","IE00B1BXHZ80.USD","IE00B4R5TH58.HKD","LU0889566641.SGD","LU1244550221.USD","SG9999001176.USD","LU2430703178.SGD","LU0345769631.USD","LU1674673428.USD","BK4534","LU0098860793.USD","IE00BDGV0183.EUR","LU0456855351.SGD","LU0203345920.USD","BK4559","BK4588","IE00BVYPNW00.USD","LU0114720955.EUR","LU0203347892.USD","LU1066051225.USD","LU1244550494.USD","IE00B3PB1722.GBP","LU2129689431.USD","LU2430703095.HKD","LU2505996681.GBP","INO","LU0234570918.USD","LU1023059063.AUD","LU0306806265.USD","SG9999001176.SGD","SG9999001440.SGD","LU2468319806.SGD","LU0345769128.USD","IE00B19Z3B42.SGD","LU0070217475.USD","LU0225284248.USD","BK4568","LU1074936037.SGD","LU1732799900.SGD","LU2471134523.USD","LU1430594728.SGD","LU1061106388.HKD","LU1221951046.USD","LU1914381329.SGD","LU0170899867.USD","LU1057294990.SGD","LU0345770993.USD","LU1894683348.USD","SG9999003800.SGD","LU2129689514.USD","IE00BBT3K403.USD","BK4583","LU0985481810.HKD","LU0321505868.SGD","LU0912757837.SGD","LU0640476718.USD","LU1162221912.USD","IE00BLSP4452.SGD","LU0225771236.USD","LU1718418525.SGD","LU2347655156.SGD","IE00BN8TJ469.HKD","IE0034235303.USD","LU0985320562.USD","LU0320765646.SGD","LU1280957306.USD","LU2505996509.AUD","LU0306807586.USD","SGXZ57979304.SGD","LU0058720904.USD","LU0289739699.SGD","LU1935042991.SGD","LU1732800096.USD","LU0466842654.USD","LU1778281490.HKD","LU0345770308.USD","LU1066051498.USD","LU2430703251.USD","LU1894683264.USD","LU2133065610.SGD","IE00B19Z3581.USD","LU1585245621.USD","LU1496350502.SGD","BK4139","IE000M9KFDE8.USD","LU1066051811.HKD","LU0868494617.USD","IE00B7SZLL34.SGD","BK4533","LU1221951129.SGD","BK4532","BK4592","LU2750360997.AUD","IE00BGHQF631.EUR","BK4550","LU1059921491.USD","LU0792757196.USD","LU2471134796.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","LU2750360641.GBP","SG9999011175.SGD","IE00BJT1NW94.SGD","LU1261432733.SGD","LU1674673691.USD","LU2602419157.SGD","IE00BFXG1179.USD","LU0122379950.USD","LU1506573853.SGD","LU0234572021.USD","IE0002270589.USD","BK4504"],"gpt_icon":0},{"id":"2590769327","title":"Director Ronald Richard Sells Common Shares of Emergent BioSolutions Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2590769327","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590769327?lang=en_us&edition=fundamental","pubTime":"2025-12-10 07:01","pubTimestamp":1765321295,"startTime":"0","endTime":"0","summary":"Ronald Richard, Director at Emergent BioSolutions Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Emergent BioSolutions Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 09, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL5MNsJv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Director Ronald Richard Sells Common Shares of Emergent BioSolutions Inc","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","EBS","BK4139"],"gpt_icon":0},{"id":"2590341840","title":"Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341840","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590341840?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:30","pubTimestamp":1765287002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA14FCX0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","LU0234570918.USD","IE00BKVL7J92.USD","BK4550","LU0882574055.USD","LU0823416689.USD","LU1674673691.USD","LU2089984988.USD","BK4139","SG9999015952.SGD","IE00B19Z3B42.SGD","LU0058720904.USD","LU2087621335.USD","LU1430594728.SGD","SG9999015945.SGD","IE00BSNM7G36.USD","LU1674673428.USD","LU2468319806.SGD","LU1066053197.SGD","BK4566","BK4532","LU0114720955.EUR","SG9999015978.USD","IE00B3T34201.USD","BK4583","BK4588","LU1585245621.USD","LU0109394709.USD","IE0002270589.USD","SG9999015986.USD","IE00B19Z3581.USD","LU1839511570.USD","LU1778281490.HKD","IE00BZ1G4Q59.USD","GILD","IE00B7SZLL34.SGD","LU0289739699.SGD","BK4578","LU0320765992.SGD","LU0889565916.HKD","LU1066051498.USD","LU2324357040.USD","LU1571399168.USD","BK4585"],"gpt_icon":0},{"id":"2590934600","title":"Barclays Initiates Viatris at Overweight With $15 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2590934600","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590934600?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:59","pubTimestamp":1765285171,"startTime":"0","endTime":"0","summary":"Viatris (VTRS) has an average rating of hold and mean price target of $12.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1839511570.USD","BK4007","VTRS","BK4585","LU2087621335.USD","BK4588","BK4583"],"gpt_icon":0},{"id":"2590834344","title":"Tonix Pharmaceuticals Names Irina Ishak General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2590834344","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590834344?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:01","pubTimestamp":1765281679,"startTime":"0","endTime":"0","summary":"Tonix Pharmaceuticals Holding Corp. has appointed Irina Ishak as General Counsel, effective December 8, 2025. She will lead the company's legal, corporate governance, and compliance functions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tonix Pharmaceuticals Holding Corp. published the original content used to generate this news brief via GlobeNewswire  on December 09, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL5w5FWj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4583","BK4585","SG9999014013.SGD","IE00B64PRP62.GBP","SG9999014021.USD","LU2210150020.SGD","BK4112","LU2095319765.USD","BK4588","LU2210149790.SGD","TNXP","IE00BKPKM429.USD","SG9999014039.USD","LU0314104364.USD","BK4139","IE00BGHQF748.EUR","SG9999014005.SGD","NDAQ"],"gpt_icon":0},{"id":"2590343147","title":"Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2590343147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590343147?lang=en_us&edition=fundamental","pubTime":"2025-12-09 20:00","pubTimestamp":1765281602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nTUA6QJYJ9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4583","TNXP","BK4139"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4583","nameEN":"BK4583"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monkeypox Concept(BK4583),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monkeypox Concept(BK4583) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monkeypox Concept,BK4583,Monkeypox Concept股票,Monkeypox Concept股票老虎,Monkeypox Concept股票老虎国际,Monkeypox Concept行情,Monkeypox Concept股票行情,Monkeypox Concept股价,Monkeypox Concept股市,Monkeypox Concept股票价格,Monkeypox Concept股票交易,Monkeypox Concept股票购买,Monkeypox Concept股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monkeypox Concept(BK4583),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monkeypox Concept(BK4583) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}